Metastatic Cancer Drug Market Scope And Analysis

Report Code : TIPRE00028616
Category : Life Sciences

Status : Published
No. of Pages : 233

Buy Now

Metastatic Cancer Drug Market Analysis, Scope, and Growth by 2028

Buy Now

Metastatic Cancer Drug Market Report Scope

Report Attribute	Details
Market size in 2021	US$ 51.16 Billion
Market Size by 2028	US$ 68.35 Billion
Global CAGR (2021 - 2028)	4.2%
Historical Data	2019-2020
Forecast period	2022-2028
Segments Covered	By Cancer Type Breast Cancer Lung Cancer Liver Cancer Hematological Cancer Brain Cancer Prostate Cancer Pancreatic Cancer By Route of Administration Intravenous Intramuscular Oral By Drug Class HER2 Inhibitor Immune Checkpoint Inhibitor PARP Inhibitor Kinase Inhibitor By Product Branded and Generic & Biosimilar
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	AbbVie Inc Amgen Inc Bristol Myers Squibb Company F HOFFMANN LA ROCHE LTD Novartis AG ASTRAZENECA PLC Eli Lilly and Company MERCK KGaA Pfizer Inc Arena Pharmaceutical GmbH

Product-Based Insights

Based on product, the metastatic cancer drug market is bifurcated into branded and generics and biosimilars. The branded segment accounted for a larger market share in 2021. However, the generics and biosimilars segment is estimated to register a higher CAGR during the forecast period.

End User-Based Insights

Based on end user, the metastatic cancer drug market is segmented into hospitals, specialty clinics, and others. The hospital segment accounted for the largest share in 2021, whereas the specialty clinic segment is estimated to register the highest CAGR during the forecast period.

Product launches and approvals are among the commonly adopted strategies by companies to expand their global footprints and product portfolios. The metastatic cancer drug market players also focus on the partnership strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name across the world. They aim to flourish their market shares with the development of innovative products.

AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; F. HOFFMANN-LA ROCHE LTD.; Novartis AG; ASTRAZENECA PLC.; Eli Lilly and Company; MERCK KGaA; and Pfizer Inc. (Arena Pharmaceutical GmbH); and Johnson and Johnson Services, Inc. are the leading companies operating in the metastatic cancer drug market.